Cite
Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma.
MLA
Khashab, Tamer, et al. “Long‐term Overall‐ and Progression‐free Survival after Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma.” British Journal of Haematology, vol. 185, no. 4, May 2019, pp. 670–78. EBSCOhost, https://doi.org/10.1111/bjh.15814.
APA
Khashab, T., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., McLaughlin, P., Rodriguez, M. A., Neelapu, S. S., Fayad, L., Younes, A., Feng, L., Vega, F., Kwak, L. W., & Samaniego, F. (2019). Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma. British Journal of Haematology, 185(4), 670–678. https://doi.org/10.1111/bjh.15814
Chicago
Khashab, Tamer, Fredrick Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter McLaughlin, M. Alma Rodriguez, et al. 2019. “Long‐term Overall‐ and Progression‐free Survival after Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma.” British Journal of Haematology 185 (4): 670–78. doi:10.1111/bjh.15814.